A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma
Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Jean‐Christophe Marine(VIB-KU Leuven Center for Cancer Biology), Ada Nowosad(Centre National de la Recherche Scientifique), Samira Makhzami(VIB-KU Leuven Center for Cancer Biology), Wim Annaert(VIB-KU Leuven Center for Microbiology), Michael Dewaele(KU Leuven), Francesca M. Bosisio(Universitair Ziekenhuis Leuven), Frank Vernaillen, Sonia Cinque(VIB-KU Leuven Center for Cancer Biology), Lukas Vanwynsberghe(VIB-KU Leuven Center for Cancer Biology), Eleonora Leucci(VIB-KU Leuven Center for Cancer Biology), Katy Vandereyken(Allen Institute for Brain Science), Thierry Voet(Wellcome Sanger Institute), Florian Rambow(Essen University Hospital), Yannick Van Herck(Universitair Ziekenhuis Leuven), Veerle Boecxstaens(Universitair Ziekenhuis Leuven), Ewout Landeloos(VIB-KU Leuven Center for Cancer Biology), Panagiotis Karras(VIB-KU Leuven Center for Cancer Biology), Joost van den Oord(KU Leuven), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Dennis Pedri(VIB-KU Leuven Center for Cancer Biology), Sam Kint(KU Leuven), Asier Antoranz(KU Leuven), Greet Bervoets(VIB-KU Leuven Center for Cancer Biology), Oliver Bechter(Universitair Ziekenhuis Leuven)
Cited by 20
Related Papers
Methods and applications for single-cell and spatial multi-omics
|Nature Reviews Genetics|2023|1.1k
Melanoma addiction to the long non-coding RNA SAMMSON
|Nature|2016|588
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
MDM4 is a key therapeutic target in cutaneous melanoma
|Nature Medicine|2012|305